Rocket Pharmaceuticals is trading 5.17% lower at $2.48 after announcing a $100 million underwritten public stock offering.
- The underwriters have a 30-day option for up to $15 million in additional shares.
- Coverage reported a 6.5% postmarket slide. A Danon disease program update is scheduled for October 6 at 4:30 p.m. ET, after the market closes.
- XBI is down 2.50% while major U.S. indices are higher; no trading-volume figure was provided.